Christie M Atchison1, Shilpa Arlikar2, Ernest Amankwah2, Irmel Ayala3, Laurie Barrett4, Brian R Branchford5, Michael Streiff6, Clifford Takemoto7, Neil A Goldenberg8. 1. Office of Graduate Medical Education, University of South Florida Morsani College of Medicine, Tampa, FL. 2. Clinical and Translational Research Organization, All Children's Research Institute, All Children's Hospital Johns Hopkins Medicine, St. Petersburg, FL. 3. Johns Hopkins Medicine Pediatric Thrombosis Program, All Children's Hospital and Johns Hopkins Children's Center, St. Petersburg, FL and Baltimore, MD. 4. Clinical and Translational Research Organization, All Children's Research Institute, All Children's Hospital Johns Hopkins Medicine, St. Petersburg, FL; Johns Hopkins Medicine Pediatric Thrombosis Program, All Children's Hospital and Johns Hopkins Children's Center, St. Petersburg, FL and Baltimore, MD. 5. Department of Pediatrics, Section of Hematology/Oncology/Bone Marrow Transplantation, University of Colorado School of Medicine Anschutz Medical Campus and Children's Hospital Colorado, Aurora, CO. 6. Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. 7. Johns Hopkins Medicine Pediatric Thrombosis Program, All Children's Hospital and Johns Hopkins Children's Center, St. Petersburg, FL and Baltimore, MD; Division of Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD. 8. Clinical and Translational Research Organization, All Children's Research Institute, All Children's Hospital Johns Hopkins Medicine, St. Petersburg, FL; Johns Hopkins Medicine Pediatric Thrombosis Program, All Children's Hospital and Johns Hopkins Children's Center, St. Petersburg, FL and Baltimore, MD; Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; Division of Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: neil@jhmi.edu.
Abstract
OBJECTIVE: To determine risk factors for pediatric hospital-associated venous thromboembolism (HA-VTE) in noncritically ill children to derive a novel HA-VTE risk model for this population. STUDY DESIGN: Patients with HA-VTE were identified retrospectively via the electronic health record at All Children's Hospital Johns Hopkins Medicine from April 10, 2013 through January 1, 2006. Seven contemporaneous, noncritically ill control children were randomly selected for each case of HA-VTE. The association between putative risk factors and HA-VTE was estimated with ORs and 95% CIs, which were calculated using the Wald method. A P-value threshold ≤.2 was used in univariate analysis for inclusion into a multivariate (adjusted) model. RESULTS: Fifty cases of HA-VTE occurred in noncritically ill children. The presence of a central venous catheter (OR 27.67, 95% CI, 8.40-91.22), infection (OR 10.40, 95% CI, 3.46-31.25), and length of stay ≥4 days (OR 5.26, 95% CI, 1.74-15.88) were found to be statistically significant risk factors for HA-VTE. An 8-point risk score was derived in which scores of 8 points, 7 points, and ≤6 points corresponded to venous thromboembolism risks of 12.5%, 1.1%, and 0.1%, respectively. CONCLUSION: The presence of a central venous catheter, infection, and length of stay ≥4 days are significant risk factors for HA-VTE in noncritically ill children, forming the basis for a new risk score that could inform venous thromboembolism prophylaxis decision-making. These findings warrant prospective validation.
OBJECTIVE: To determine risk factors for pediatric hospital-associated venous thromboembolism (HA-VTE) in noncritically ill children to derive a novel HA-VTE risk model for this population. STUDY DESIGN:Patients with HA-VTE were identified retrospectively via the electronic health record at All Children's Hospital Johns Hopkins Medicine from April 10, 2013 through January 1, 2006. Seven contemporaneous, noncritically ill control children were randomly selected for each case of HA-VTE. The association between putative risk factors and HA-VTE was estimated with ORs and 95% CIs, which were calculated using the Wald method. A P-value threshold ≤.2 was used in univariate analysis for inclusion into a multivariate (adjusted) model. RESULTS: Fifty cases of HA-VTE occurred in noncritically ill children. The presence of a central venous catheter (OR 27.67, 95% CI, 8.40-91.22), infection (OR 10.40, 95% CI, 3.46-31.25), and length of stay ≥4 days (OR 5.26, 95% CI, 1.74-15.88) were found to be statistically significant risk factors for HA-VTE. An 8-point risk score was derived in which scores of 8 points, 7 points, and ≤6 points corresponded to venous thromboembolism risks of 12.5%, 1.1%, and 0.1%, respectively. CONCLUSION: The presence of a central venous catheter, infection, and length of stay ≥4 days are significant risk factors for HA-VTE in noncritically ill children, forming the basis for a new risk score that could inform venous thromboembolism prophylaxis decision-making. These findings warrant prospective validation.
Authors: A Hanslik; E Kitzmüller; K Thom; M Haumer; W Mlekusch; U Salzer-Muhar; I Michel-Behnke; C Male Journal: J Thromb Haemost Date: 2011-12 Impact factor: 5.824
Authors: Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Neil A Goldenberg; Marco P Donadini; Susan R Kahn; Mark Crowther; Gili Kenet; Ulrike Nowak-Göttl; Marilyn J Manco-Johnson Journal: Haematologica Date: 2010-06-30 Impact factor: 9.941
Authors: Clifford M Takemoto; Sajeet Sohi; Kruti Desai; Raman Bharaj; Anuj Khanna; Susan McFarland; Sybil Klaus; Alia Irshad; Neil A Goldenberg; John J Strouse; Michael B Streiff Journal: J Pediatr Date: 2013-12-12 Impact factor: 4.406
Authors: Paul Monagle; Andrew Cochrane; Robin Roberts; Cedric Manlhiot; Robert Weintraub; Barbara Szechtman; Marina Hughes; Maureen Andrew; Brian W McCrindle Journal: J Am Coll Cardiol Date: 2011-08-02 Impact factor: 24.094
Authors: Sheila J Hanson; Rowena C Punzalan; Marjorie J Arca; Pippa Simpson; Melissa A Christensen; Sydney K Hanson; Ke Yan; Kristin Braun; Peter L Havens Journal: J Trauma Acute Care Surg Date: 2012-05 Impact factor: 3.313
Authors: A A Sharathkumar; A Mahajerin; L Heidt; K Doerfer; M Heiny; T Vik; R Fallon; A Rademaker Journal: J Thromb Haemost Date: 2012-07 Impact factor: 5.824
Authors: Arash Mahajerin; Brian R Branchford; Ernest K Amankwah; Leslie Raffini; Elizabeth Chalmers; C Heleen van Ommen; Neil A Goldenberg Journal: Haematologica Date: 2015-05-22 Impact factor: 9.941
Authors: Benjamin A Goldstein; Ann Marie Navar; Michael J Pencina; John P A Ioannidis Journal: J Am Med Inform Assoc Date: 2016-05-17 Impact factor: 4.497
Authors: Jennifer Yen; Kyle J Van Arendonk; Michael B Streiff; LeAnn McNamara; F Dylan Stewart; Kim G Conner; Richard E Thompson; Elliott R Haut; Clifford M Takemoto Journal: Pediatr Crit Care Med Date: 2016-05 Impact factor: 3.624
Authors: Julie Jaffray; Arash Mahajerin; Brian Branchford; Anh Thy H Nguyen; E Vincent S Faustino; Michael Silvey; Stacy E Croteau; John H Fargo; James D Cooper; Nihal Bakeer; Neil A Zakai; Amy Stillings; Emily Krava; Ernest K Amankwah; Guy Young; Neil A Goldenberg Journal: Pediatr Crit Care Med Date: 2022-01-01 Impact factor: 3.971
Authors: Shannon C Walker; C Buddy Creech; Henry J Domenico; Benjamin French; Daniel W Byrne; Allison P Wheeler Journal: Pediatrics Date: 2021-05-19 Impact factor: 9.703